Repligen
RGEN
$180.71
+2.16%
Repligen Corp is a Waltham, Massachusetts-based life sciences company that develops and sells bioprocessing equipment and supplies — filtration and fluid management, chromatography, proteins, and process analytics — used by biopharmaceutical companies and CDMOs to manufacture monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. With roughly 2,000 employees and a market capitalization near $9.2 billion, Repligen is a focused, high-margin niche supplier rather than a diversified tools conglomerate, deriving about 55% of revenue from filtration, 21% from chromatography, 13% from process analytics, and 11% from proteins, with a geographic mix of roughly 44% North America, 37% Europe, and 19% Asia-Pacific. The current investor narrative centers on a bioprocessing demand recovery: after a multi-year destocking downturn that crushed 2024 profitability (a Q4 2024 net loss of $33.9 million), revenue has reaccelerated to 14.8% year-over-year growth in the March 2026 quarter, and the stock has responded with a 42% one-year gain. Debate now hinges on whether this recovery is durable — bulls point to the strong_buy consensus and M&A appetite in life sciences tools (evidenced by Merck KGaA's premium bid for Bio-Techne), while bears flag an extremely rich valuation and thin net margins that leave little room for execution error.…
RGEN
Repligen
$180.71
Related headlines
Investment Opinion: Should I buy RGEN Today?
The synthesized recommendation is Hold. While the analyst consensus is strong_buy with an average target of $189.48 implying 7.1% upside, the risk/reward is balanced at the current price of $176.89 given the extreme valuation and thin margins. The core thesis is that Repligen is a high-quality bioprocessing franchise in the early stages of a demand recovery, but the market has already priced in much of the earnings inflection, leaving limited margin of safety for new capital.
Supporting evidence for the Hold rating includes: revenue growth of 14.83% year-over-year in Q1 2026, which is solid but not explosive relative to the 66.75x forward PE; a gross margin of 50.70% that is high but compressing; free cash flow of $104.11 million on a trailing-twelve-month basis, which is positive but yields a price-to-free-cash-flow ratio of 284x; and a fortress balance sheet with $582.65 million in cash and a 0.33 debt-to-equity ratio. The implied upside to the average analyst target of $189.48 is only 7.1%, which is modest compensation for the downside risk to the $145 low target (-18%) or the 52-week low of $100.99 (-43%). The stock's 42.22% one-year gain versus SPY's 15.01% shows that much of the recovery optimism is already reflected in the price.
The biggest risks that could invalidate the Hold thesis are a stall in the bioprocessing recovery, continued gross margin compression, and multiple compression if earnings fail to meet the aggressive forward estimates. This Hold would upgrade to Buy if the forward PE compresses below 50x through earnings growth while revenue growth accelerates above 20%, or if the stock pulls back to the $145-$150 range where the risk/reward becomes more favorable. It would downgrade to Sell if revenue growth decelerates below 10% or if gross margins fall below 48%, signaling that the recovery is losing steam. Relative to its own history, the stock is overvalued on trailing earnings but fairly valued on forward earnings if the recovery continues; relative to peers, it trades at a significant premium that requires flawless execution to justify.
Sign up to view all
RGEN 12-Month Price Forecast
Repligen presents a classic recovery story where the operational inflection is real but the valuation already discounts much of the upside. Revenue growth of 14.83% and a strong_buy consensus are encouraging, but the 66.75x forward PE and 12.48x price-to-sales ratio leave no room for error, especially with gross margins compressing and free cash flow declining sequentially. The stock's 42.22% one-year gain and position at 86% of its 52-week range suggest momentum is strong but overextension risk is elevated. I would upgrade to bullish if revenue growth accelerates above 18% with gross margin recovery above 52%, or if the stock pulls back to the $145-$150 range where the risk/reward becomes compelling. I would downgrade to bearish if revenue growth decelerates below 10% or if gross margins fall below 48%, signaling that the recovery is losing steam.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Repligen's 12-month outlook, with a consensus price target around $189.48 and implied upside of +4.8% versus the current price.
Average Target
$189.48
0 analysts
Implied Upside
+4.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$145 - $225
Analyst target range
Coverage is robust, with 21 analysts following Repligen and a consensus recommendation of strong_buy (recommendation mean of 1.478 on a 1-5 scale where 1 is a strong buy). The average price target is $189.48, which implies approximately +7.1% upside from the current price of $176.89 — a modest but positive expected return. The consensus clearly leans bullish, and the institutional ratings flow supports this: Benchmark upgraded to Buy from Hold on July 7, 2026, while Evercore ISI, HSBC, JP Morgan, Barclays, and HC Wainwright have all maintained Buy or Outperform-equivalent ratings through 2026, with no downgrades visible in the recent record.
The target range spans $145.00 to $225.00, a spread of $80, or roughly 45% of the current price — a wide dispersion that signals meaningful disagreement about the pace of the bioprocessing recovery. The high target of $225 implies roughly +27% upside and likely assumes accelerating revenue growth, margin expansion toward historical peaks, and multiple expansion as earnings normalize; the low target of $145 implies about -18% downside and likely prices in a stall in the recovery, continued margin compression, or a broader life sciences tools de-rating. The tight clustering of recent ratings around Buy/Outperform, combined with the strong_buy consensus and the Benchmark upgrade, suggests analysts are becoming more constructive, but the wide target spread means investors should treat the consensus as a directional signal rather than a precise price forecast.
Bulls vs Bears: RGEN Investment Factors
The bull case currently has stronger evidence, anchored by a genuine revenue reacceleration to 14.83% year-over-year growth, a fortress balance sheet with $582.65 million in cash and a 0.33 debt-to-equity ratio, and a unanimous strong_buy analyst consensus with a $189.48 average target. However, the bear case is not without merit: the trailing PE of 188.34x and forward PE of 66.75x leave essentially no margin of safety, while net margin of 4.29% and ROE of 2.32% show profitability has not yet caught up to the valuation. The single most important tension is whether the bioprocessing recovery is durable enough to drive the earnings inflection the market is pricing in — if forward EPS of $5.376 materializes, the forward PE compresses to a more digestible 66.75x, but any stall in order momentum would expose the stock to a severe multiple compression. With the stock up 42.22% over one year versus SPY's 15.01%, much of the recovery optimism is already reflected in the price, making execution risk asymmetric to the downside.
Bullish
- Revenue reacceleration confirms recovery: Q1 2026 revenue of $194.26 million grew 14.83% year-over-year, up from $169.17 million in Q1 2025, marking a decisive inflection from the 2024 destocking trough when quarterly revenue hovered around $155-$168 million. The sequential trend is also firm, with revenue climbing from $182.37 million in Q2 2025 to $197.91 million in Q4 2025, suggesting underlying bioprocessing demand has stabilized and is expanding again.
- Fortress balance sheet with minimal leverage: Repligen holds $582.65 million in cash against a debt-to-equity ratio of just 0.33 and a current ratio of 8.37, providing enormous financial flexibility to fund R&D, pursue bolt-on acquisitions, or weather a demand slowdown. This liquidity removes near-term solvency risk and allows the company to invest through the cycle without dilutive equity raises.
- Strong analyst consensus and upgrade momentum: All 21 covering analysts rate the stock a strong_buy (recommendation mean of 1.478), with an average price target of $189.48 implying roughly 7.1% upside from $176.89. Benchmark upgraded to Buy from Hold on July 7, 2026, and Evercore ISI, HSBC, JP Morgan, Barclays, and HC Wainwright have all maintained bullish ratings through 2026 with no visible downgrades.
- High gross margins and oligopolistic niche: Gross margin of 50.70% in Q1 2026, while down from 53.65% a year earlier, remains robust for a tools supplier and reflects Repligen's entrenched position in the oligopolistic bioprocessing consumables market. Filtration alone accounts for roughly 55% of revenue, giving the company pricing power and recurring consumable demand tied to biologics manufacturing volumes.
Bearish
- Extreme valuation leaves no margin of safety: The trailing PE of 188.34x and forward PE of 66.75x are extraordinarily rich, with the forward multiple implying earnings must roughly triple to justify the price. Price-to-sales of 12.48x and EV/EBITDA of 56.84x further underscore that investors are paying a massive premium for a business with a 6.62% net margin.
- Thin and compressing profitability: Q1 2026 net income was just $8.33 million on a 4.29% net margin, and gross margin has slipped from 53.65% in Q1 2025 to 50.70% in Q1 2026. The gap between 50.7% gross margin and 9.3% operating margin highlights a heavy $80.49 million operating expense load that constrains bottom-line leverage.
- Weak returns on capital: ROE of just 2.32% and ROA of 1.40% are very low for a company trading at these multiples, reflecting both a capital-heavy balance sheet and compressed earnings. Shareholders are not yet being compensated with attractive returns on capital despite the premium valuation.
- Free cash flow deterioration: Q1 2026 free cash flow of $23.35 million represents a steep decline from the $42.71 million generated in Q3 2025, partly due to a $21.90 million working capital drag. The price-to-free-cash-flow ratio of 284x shows the stock is priced for a dramatic cash flow inflection that has not yet materialized.
RGEN Technical Analysis
Repligen is in a sustained, powerful uptrend: the shares have gained 42.22% over the past year versus just 15.01% for SPY, a relative strength advantage of 27.21 percentage points, and the current price of $176.89 sits at approximately 86% of the 52-week range (52-week low $100.99, high $188.73). That positioning near the upper end of the range signals strong momentum but also meaningful overextension risk — the stock is only about 6% below its high, meaning buyers have consistently defended pullbacks. The 55.33% six-month gain confirms this is a broad, persistent advance rather than a short-lived spike, though the trailing max drawdown of -40.28% is a reminder that this name can correct violently when the bioprocessing cycle turns.
Short-term momentum remains constructive but is decelerating relative to the spring surge. The 1-month change of +0.30% is essentially flat, while the 3-month change of +33.99% shows the bulk of recent gains were booked between June and August; the 1-month relative strength versus SPY of +1.26% indicates only modest outperformance lately. This divergence — a flat month inside a strong quarter and year — suggests the stock is consolidating recent gains rather than reversing, a healthy pause after a run from roughly $116 in late March to $188.73 at the peak. Notably, the year-to-date gain of just 7.63% versus SPY's 11.70% (relative strength -4.07% YTD) implies the stock actually lagged early in 2026 before the summer breakout, so the current consolidation is occurring from a position of recovered strength, not exhaustion of a long base.
Key technical levels are well defined: support rests at the 52-week low of $100.99, with a nearer psychological and structural floor around the $160-$165 area where the stock consolidated in early September, while resistance is the 52-week high of $188.73. A decisive breakout above $188.73 on volume would confirm the uptrend's continuation and likely open a move toward the analyst high target of $225, whereas a breakdown below $160 would signal that the summer rally is unwinding and put the $145 analyst low target in play. With a beta of 1.048, Repligen moves roughly in line with the market on a volatility basis — only about 5% more volatile than SPY — which is surprisingly tame for a high-multiple life sciences tools name and suggests position sizing need not be dramatically reduced relative to a broad index allocation, though the -40.28% max drawdown argues for disciplined stops.
Beta
1.05
1.05x market volatility
Max Drawdown
-40.3%
Largest decline past year
52-Week Range
$101-$189
Price range past year
Annual Return
+47.8%
Cumulative gain past year
| Period | RGEN Return | S&P 500 |
|---|---|---|
| 1m | -0.2% | +1.0% |
| 3m | +43.0% | +5.4% |
| 6m | +58.1% | +17.8% |
| 1y | +47.8% | +16.5% |
| ytd | +10.0% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RGEN Fundamental Analysis
Repligen's revenue trajectory has inflected decisively upward. The most recent quarter (Q1 2026, ended March 31, 2026) delivered revenue of $194.26 million, up 14.83% year-over-year from $169.17 million in Q1 2025, and the sequential trend is equally firm: $182.37 million in Q2 2025, $188.81 million in Q3 2025, $197.91 million in Q4 2025, and $194.26 million in Q1 2026. The product segment overwhelmingly drives the business at $194.21 million of the $194.26 million total, with royalties a negligible $44,000 — meaning growth is entirely a function of bioprocessing hardware and consumables demand. This reacceleration from the 2024 trough, when quarterly revenue hovered around $155-$168 million, supports the thesis that customer destocking has ended and underlying biologics manufacturing activity is recovering, though the modest sequential dip from Q4 to Q1 warrants monitoring.
Profitability is positive but thin, and margin trends are mixed. Q1 2026 net income was $8.33 million on a 4.29% net margin, with gross margin of 50.70% — a solid level for a tools supplier but down from 53.24% in Q3 2025 and 53.65% in Q1 2025. The company swung from a Q4 2024 net loss of $33.87 million (a -20.21% net margin driven by a $128.71 million cost of revenue spike) to consistent profitability across all four quarters of 2025 and into 2026, with quarterly net income ranging from $5.83 million to $14.91 million. Operating margin of 9.26% in Q1 2026 is an improvement from 3.89% a year earlier, but the gap between 50.7% gross margin and 9.3% operating margin highlights a heavy operating expense load — $80.49 million in Q1 2026, including $14.46 million of R&D — that constrains bottom-line leverage.
The balance sheet is exceptionally strong, but cash generation is only moderate. The current ratio stands at 8.37 and the debt-to-equity ratio is a conservative 0.33, with $582.65 million of cash at the end of Q1 2026 against minimal debt obligations — a fortress liquidity position that removes near-term solvency risk. Free cash flow on a trailing-twelve-month basis is $104.11 million, and Q1 2026 free cash flow was $23.35 million on operating cash flow of $28.30 million, but this represents a steep decline from the $42.71 million generated in Q3 2025, partly due to a $21.90 million working capital drag. ROE of just 2.32% and ROA of 1.40% are very low for a company trading at these multiples, reflecting both the capital-heavy balance sheet and compressed earnings — the company funds itself internally with ease, but shareholders are not yet being compensated with attractive returns on capital.
Quarterly Revenue
$194255000.0B
2026-03
Revenue YoY Growth
+14.8%
YoY Comparison
Gross Margin
50.7%
Latest Quarter
Free Cash Flow
$104112000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RGEN Overvalued?
Because Repligen is profitable (Q1 2026 net income of $8.33 million), the PE ratio is the appropriate primary metric — but it is eye-watering. The trailing PE is 188.34x, while the forward PE is 66.75x, an enormous gap that implies the market expects earnings to roughly triple over the next year, consistent with the analyst consensus EPS estimate of $5.376 versus trailing EPS of just $0.0053. The PEG ratio of -0.65 is not meaningful given the distorted trailing earnings base, and the price-to-sales ratio of 12.48x and EV/sales of 12.66x confirm that investors are paying a steep premium for a business with a 6.62% net margin.
Relative to the medical instruments and supplies sector, Repligen trades at a substantial premium. A trailing PE of 188.34x and forward PE of 66.75x compare unfavorably to typical sector multiples in the 20-30x range, implying a premium of well over 100% on trailing earnings and roughly 120-230% on forward earnings depending on the peer set. The price-to-book ratio of 4.38x and price-to-cash-flow of 78.48x further underscore the richness. This premium is partially justified by Repligen's recovery-driven growth (14.83% revenue growth), high gross margins near 50%, and its entrenched position in the oligopolistic bioprocessing consumables market, but the current multiple leaves essentially no margin of safety if growth disappoints.
Historically, Repligen's valuation has been volatile but generally elevated. The PE ratio ranged from roughly 45x-64x in 2022, spiked above 100x during the 2023-2024 earnings trough (including a meaningless negative reading in Q4 2024), and now sits at 188x on trailing earnings — near the top of its own historical band, though the forward PE of 66.75x is more in line with the 2022-2023 range. The PS ratio of 12.48x is actually well below the 34-67x readings seen in 2021-2024, reflecting the revenue recovery, but the price-to-free-cash-flow ratio of 284x (versus 175-543x historically) shows the stock is still priced for a dramatic earnings and cash flow inflection that has not yet materialized.
PE
188.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 45x~196x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
56.8x
Enterprise Value Multiple
Investment Risk Disclosure
Repligen's financial risks center on its thin profitability and dependence on continued growth to justify valuation. Q1 2026 net income was just $8.33 million on a 4.29% net margin, and gross margin has compressed from 53.65% in Q1 2025 to 50.70% in Q1 2026, indicating that the revenue recovery is not yet translating into robust bottom-line leverage. Free cash flow declined to $23.35 million in Q1 2026 from $42.71 million in Q3 2025 due to a $21.90 million working capital drag, and ROE of 2.32% and ROA of 1.40% are very low for a company trading at 188x trailing earnings. The company's $582.65 million cash position and 0.33 debt-to-equity ratio mitigate solvency risk, but the heavy $80.49 million quarterly operating expense load, including $14.46 million of R&D, means any revenue shortfall would quickly erode earnings.
Market and competitive risks are dominated by extreme valuation compression risk. At a trailing PE of 188.34x and forward PE of 66.75x, Repligen trades at a premium of well over 100% to the medical instruments sector's typical 20-30x range, leaving the stock highly vulnerable to any disappointment in the bioprocessing recovery narrative. The beta of 1.048 means the stock moves roughly in line with the market, but its -40.28% max drawdown demonstrates that sector-specific shocks can cause violent corrections. Competitive disruption from larger, diversified tools players like Danaher and Thermo Fisher, which can bundle bioprocessing offerings, poses a persistent threat, while the Merck KGaA-Bio-Techne deal highlights both M&A appetite and the risk that Repligen could be disadvantaged if competitors consolidate. Macro sensitivity to biopharma R&D budgets and CDMO capacity utilization remains a key swing factor.
The worst-case scenario would involve a stall in the bioprocessing recovery, perhaps triggered by a slowdown in biologics manufacturing activity or customer destocking resuming, causing revenue growth to decelerate below 10% and forward EPS estimates to be revised sharply lower. In this scenario, the forward PE of 66.75x would compress toward the sector average, and the stock could retest its 52-week low of $100.99, representing a decline of approximately -43% from the current price of $176.89. The analyst low target of $145 implies about -18% downside and likely prices in a stall in the recovery, but a more severe de-rating could push shares below that level toward the 52-week low. Investors should note that the trailing max drawdown of -40.28% is a realistic guide to the damage this name can suffer in an adverse cycle.
FAQ
The most severe risk is valuation compression: at 188x trailing earnings and 66.75x forward earnings, any disappointment in the bioprocessing recovery could trigger a sharp de-rating toward the sector average, potentially driving the stock toward the $145 low target or the $100.99 52-week low. Financial risks include thin net margins of 4.29%, compressing gross margins (down from 53.65% to 50.70% year-over-year), and declining free cash flow ($23.35 million in Q1 2026 versus $42.71 million in Q3 2025). Competitive risks stem from larger, diversified tools players like Danaher and Thermo Fisher that can bundle bioprocessing offerings, as well as the risk that sector consolidation disadvantages Repligen. Macro risks include sensitivity to biopharma R&D budgets and CDMO capacity utilization, with a beta of 1.048 indicating the stock moves roughly in line with the market but with a history of -40.28% max drawdown.
The 12-month forecast is base-case weighted, with a 55% probability that RGEN trades between $180 and $200, reflecting continued mid-teens revenue growth and gradual multiple compression as earnings normalize toward the $5.376 consensus. The bull case (25% probability) targets $210-$225, driven by accelerating revenue growth above 20% and margin recovery, while the bear case (20% probability) targets $100-$145 if the recovery stalls and multiple compression ensues. The most likely scenario assumes revenue growth of 14-16%, gross margin stabilization at 50-51%, and forward EPS meeting consensus, which would keep the stock near the analyst average target of $189.48. The key assumption behind the base case is that bioprocessing demand continues to recover without a renewed destocking cycle.
RGEN is significantly overvalued on trailing metrics and richly valued on forward metrics. The trailing PE of 188.34x and price-to-sales of 12.48x are near the top of the stock's own historical band and represent a premium of well over 100% to the medical instruments sector's typical 20-30x PE range. The forward PE of 66.75x is more reasonable but still assumes earnings roughly triple from trailing levels, with a consensus EPS estimate of $5.376 versus trailing EPS of just $0.0053. The market is pricing in a dramatic earnings and cash flow inflection that has not yet materialized, as evidenced by the 284x price-to-free-cash-flow ratio. Until profitability catches up, the stock remains vulnerable to multiple compression.
From a risk/reward perspective, RGEN is a Hold rather than a compelling buy at the current price of $176.89. The analyst consensus is strong_buy with an average target of $189.48, implying only 7.1% upside, which is modest compensation for the downside risk to the $145 low target (-18%) or the 52-week low of $100.99 (-43%). The company's revenue growth of 14.83% and fortress balance sheet are attractive, but the 66.75x forward PE and 4.29% net margin leave little room for execution error. It could be a good buy for long-term investors if the stock pulls back to the $145-$150 range, where the risk/reward becomes more favorable, or if revenue growth accelerates above 18% with margin expansion.
RGEN is better suited for long-term investment than short-term trading, given its high valuation, thin margins, and dependence on a multi-year bioprocessing recovery that will take time to fully materialize. The stock's beta of 1.048 is relatively tame, but its -40.28% max drawdown and 42.22% one-year gain show it can be volatile, making short-term trading risky without disciplined stops. The company pays no dividend (payout ratio of 0), so returns depend entirely on capital appreciation, which requires patience as earnings inflect. A minimum holding period of 2-3 years is suggested to allow the recovery to play out and for the forward PE to compress through earnings growth rather than price declines. Short-term traders could exploit the well-defined technical levels of $160 support and $188.73 resistance, but the risk/reward favors long-term positioning.